Comprehensive fitness landscape of SARS-CoV-2 Mpro reveals insights into viral resistance mechanisms
Julia M. FlynniD, Neha Samant, Gily S. NachumiD, David T. Barkan, Neşe Kurt YılmaziD, Celia A. SchifferiD, Stephanie A. MoquiniD, Dustin DovalaiD, Daniel N. A. BoloniD
Abstract
With the continual evolution of new strains of SARS-CoV-2 that are more virulent, transmissible, and able to evade current vaccines, there is an urgent need for effective anti-viral drugs. SARS-CoV-2 main protease (Mpro) is a leading target for drug design due to its conserved and indispensable role in the viral life cycle. Drugs targeting Mpro appear promising but will elicit selection pressure for resistance. To understand resistance potential in Mpro, we performed a comprehensive mutational scan of the protease that analyzed the function of all possible single amino acid changes. We developed three separate high-throughput assays of Mpro function in yeast, based on either the ability of Mpro variants to cleave at a defined cut-site or on the toxicity of their expression to yeast. We used deep sequencing to quantify the functional effects of each variant in each screen. The protein fitness landscapes from all three screens were strongly correlated, indicating that they captured the biophysical properties critical to Mpro function. The fitness landscapes revealed a non-active site location on the surface that is extremely sensitive to mutation making it a favorable location to target with inhibitors. In addition, we found a network of critical amino acids that physically bridge the two active sites of the Mpro dimer. The clinical variants of Mpro were predominantly functional in our screens, indicating that Mpro is under strong selection pressure in the human population. Our results provide predictions of mutations that will be readily accessible to Mpro evolution and that are likely to contribute to drug resistance. This complete mutational guide of Mpro can be used in the design of inhibitors with reduced potential of evolving viral resistance.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 121
- FWCI
- 12.57
- Field percentile
- top 1%
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Sequence Characterization and Molecular Modeling of Clinically Relevant Variants of the SARS-CoV-2 Main Protease
Thomas J. Cross, Gemma R. Takahashi, … Rachel W. Martin·BiochemistryPeer-reviewed·Sep 15, 2020
- Contributions of hyperactive mutations in Mpro from SARS-CoV-2 to drug resistance
J. M. Flynn, S. N. Zvornicanin, … D. Bolon·bioRxiv·Sep 28, 2023
- Systematic analyses of the resistance potential of drugs targeting SARS-CoV-2 main protease
Julia M. Flynn, Qiu Yu J. Huang, … Daniel N. A. Bolon·ACS Infectious DiseasesPeer-reviewed·Jun 30, 2023
- SARS-CoV-2 Mpro protease variants of concern display altered viral and host target processing but retain potency towards antivirals
S. A. Chen, E. Arutyunova, … M. J. Lemieux·bioRxiv·Jan 28, 2023
- Structural and Evolutionary Analysis Indicate that the SARS-CoV-2 Mpro is an Inconvenient Target for Small-Molecule Inhibitors Design
Maria Bzówka, Karolina Mitusińska, … Artur Góra·International Journal of Molecular SciencesPeer-reviewed·Apr 28, 2020
- Defining the Substrate Envelope of SARS-CoV-2 Main Protease to Predict and Avoid Drug Resistance
A. M. Shaqra, S. Zvornicanin, … C. A. Schiffer·bioRxiv·Jan 25, 2022